What does this research mean for the field?

Dual-drug combinations of RNA-dependent RNA polymerase inhibitors, particularly remdesivir combined with favipiravir or molnupiravir, demonstrate marked synergistic antiviral activity and dose-dependent mutagenesis against RSVA and hPIV3 while preserving epithelial integrity. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate the antiviral effectiveness of polymerase inhibitors against RSVA and hPIV3 in epithelial cell models.

May 31, 2026npj Antimicrobials and ResistanceOpen Access

Remdesivir showed the greatest potency across both viruses, and dual-drug combinations (remdesivir-favipiravir, remdesivir-molnupiravir, favipiravir-molnupiravir) produced marked synergy against RSVA.

View Full Paper

Ask AI

Bookmark

Population

Epithelial cell lines and primary human airway culture models infected with respiratory syncytial virus and…

Design

Preclinical

Authors

SESamuel Ellis AJAmy Jacobs SZShengyuan Zhang

Discussion

Member takes

Overview

In vitro RdRp inhibitor data against RSVA/hPIV3 are hypothesis-generating; clinical efficacy remains untested and should not alter practice.

Key Points

This research aims to evaluate the antiviral effectiveness of polymerase inhibitors against RSVA and hPIV3 in epithelial cell models.
Assessed four RdRp inhibitors as monotherapy and in dual-drug combinations.
Utilized epithelial cell lines and primary human airway cultures for antiviral efficacy.
Measured viral disruption of ciliary function and monitored mutational signatures.
Remdesivir displayed the highest antiviral potency against both viruses.
Combination therapies showed marked synergy for RSVA, with effective concentrations preserving epithelial integrity.
Higher antiviral exposure correlated with increased RSVA mutation burden in primary airway cultures.

Structured PICO

Population

Epithelial cell lines and primary human airway culture models infected with respiratory syncytial virus (subtype A, RSVA) and human parainfluenza (serotype 3, hPIV3)

Intervention

RNA-dependent RNA polymerase (RdRp) inhibitors (remdesivir, ribavirin, favipiravir, and molnupiravir) as monotherapy or dual-drug combinations

Outcome

Antiviral activity (inhibition), preservation of epithelial integrity, attenuation of viral disruption of ciliary function, and mutational signaturessurrogate

RdRp inhibitor combinations demonstrate synergistic antiviral activity against RSVA and hPIV3 in primary human airway culture models, highlighting their potential for broad-spectrum antiviral regimens.

Cite This Study

Ellis et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd1b05783ba022b6fd333 https://doi.org/10.1038/s44259-026-00222-7

View Full Paper

Ask AI

Bookmark

May 31, 2026npj Antimicrobials and ResistanceOpen Access

Remdesivir showed the greatest potency across both viruses, and dual-drug combinations (remdesivir-favipiravir, remdesivir-molnupiravir, favipiravir-molnupiravir) produced marked synergy against RSVA.

View Full Paper

Ask AI

Bookmark

Population

Epithelial cell lines and primary human airway culture models infected with respiratory syncytial virus and…

Design

Preclinical

Authors

SESamuel Ellis AJAmy Jacobs SZShengyuan Zhang

Discussion

Member takes

Overview

In vitro RdRp inhibitor data against RSVA/hPIV3 are hypothesis-generating; clinical efficacy remains untested and should not alter practice.

Key Points

This research aims to evaluate the antiviral effectiveness of polymerase inhibitors against RSVA and hPIV3 in epithelial cell models.
Assessed four RdRp inhibitors as monotherapy and in dual-drug combinations.
Utilized epithelial cell lines and primary human airway cultures for antiviral efficacy.
Measured viral disruption of ciliary function and monitored mutational signatures.
Remdesivir displayed the highest antiviral potency against both viruses.
Combination therapies showed marked synergy for RSVA, with effective concentrations preserving epithelial integrity.
Higher antiviral exposure correlated with increased RSVA mutation burden in primary airway cultures.

Structured PICO

Population

Epithelial cell lines and primary human airway culture models infected with respiratory syncytial virus (subtype A, RSVA) and human parainfluenza (serotype 3, hPIV3)

Intervention

RNA-dependent RNA polymerase (RdRp) inhibitors (remdesivir, ribavirin, favipiravir, and molnupiravir) as monotherapy or dual-drug combinations

Outcome

Antiviral activity (inhibition), preservation of epithelial integrity, attenuation of viral disruption of ciliary function, and mutational signaturessurrogate

Cite This Study

Ellis et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd1b05783ba022b6fd333 https://doi.org/10.1038/s44259-026-00222-7

View Full Paper

Ask AI

Bookmark